Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

SueWallSt is notifying investors of a pending investigation into Xenon Pharmaceuticals Inc. (XENE) following an enrollment pause in its Phase 3 depression trials for azetukalner. Xenon Pharmaceuticals shares fell as much as 27.6% after the company disclosed the pause in new patient enrollment for its Phase 3 azetukalner trials for major depressive disorder and bipolar depression. The pause followed a safety review concerning neuropsychiatric adverse events, including confusion, speech difficulties, coordination problems, and psychotic episodes, which had not appeared in earlier studies. Analysts reacted negatively, with Needham removing sales projections and Deutsche Bank downgrading XENE to Hold, while price targets were cut across the board. The company stated that already-randomized patients remain on study and topline data is expected in the first quarter of 2027. Investors who purchased XENE shares and suffered losses are encouraged to have their losses evaluated. The investigation concerns whether Xenon Pharmaceuticals Inc. made materially false or misleading statements regarding the safety profile and clinical development of azetukalner. Investors who purchased XENE stock or securities and suffered financial losses may be eligible to participate.